HTG2014-Section-Header-publications

Categories

Filter by Topics

AACR2023 ALK aplastic anemia AA Autoimmune Disorder B-cell lymphoma Biology of neoplasia Biomarkers Bladder Cancer bone Brain Breast Cancer CD3 Cells Cerebrospinal Fluid clinical trial cold tumor Colorectal cancer Comparison study CXCL12 Cytokines Developmental Immunotherapy Developmental Therapeutics Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Drug sensitivity EHE cancer Encephalophy EPCORE NHL-1 ERBB3 FFPE Gene Expression Profiling Genetic Polymorphism Heart Histone Deacetylase Inhibitors hot tumor HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System HTP Immune Checkpoint Inhibitors Immune Response Immune-related Colitis Immuno-Oncology IMMUNOSARC Immunotherapy IOA- 244 IRP Kidney Liposarcoma Liver liver Lung lungs lymphoma Lymphoma melanoma Melanoma Microenvironment miRNA miRNA WTA Molecular Characterization Nash and Fibrosis Natural Killer Cells Nestin+ Neurologic non-Hodgkin Lymphoma Non-Hodgkin lymphoma NHL OBP Oesophageal Adenocarcinoma Oral cancer oral squamous cell carcinoma OSCC PanB Pancreas pancreatic ductal adenocarcinoma PDAC Parkinson's Disease Pathway Analysis PDX model PI3K inhibitors PIP Plasma Platform Comparison Programmed cell death protein 1 Prostate qNPA qPCR Radioimmunotherapy Rheumatoid Arthritis Sarcoma Serum Signatures soft tissue sarcoma Sub-typing Survival plots T cells Thymic Carcinoma Tislelizumab TME Transplantation Treatment Outcome Treatment Targets Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes Zanubrutinlb

2021

CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study.

Pascual, J., et al. CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study. J Clin Oncol 39, 2021 (suppl 15; abstr 1014) DOI: 10.1200/JCO.2021.39.15_suppl.1014

View External Link

Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.

Denkert, C., et al. Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease. J Clin Oncol 39, 2021 (suppl 15; abstr 519) DOI: 10.1200/JCO.2021.39.15_suppl.519

View External Link

Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.

Marmé, F., et al. Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B. J Clin Oncol 39, 2021 (suppl 15; abstr 518). DOI 10.1200/JCO.2021.39.15_suppl.518

View External Link

MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology.

Jose Antonio Lopez Guerrero, et al. MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology. J Clin Oncol 39, 2021 (suppl 15; abstr 558) DOI 10.1200/JCO.2021.39.15_suppl.558

View External Link

2019

Gene expression comparison between primary triple-negative breast cancer and matched axillary lymph node metastasis

Srour, M. et al. Gene expression comparison between primary triple-negative breast cancer and matched axillary lymph node metastasis. Poster session presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; 2019 Jun 2, Chicago, IL.

Download pdf 1.2MB
View External Link

Page last updated May 22, 2023